The use of mode of action information in risk assessment: Quantitative key events/dose-response framework for modeling the dose-response for key events

Critical Reviews in Toxicology

Volumn 44, Issue SUPPL.3, 2014, Pages 17-43

  Simon, Ted W ^a   Simons Jr , S Stoney ^b   Preston, R Julian ^c   Boobis, Alan R ^d   Cohen, Samuel M ^e   Doerrer, Nancy G ^f   Fenner Crisp, Penelope A ^g   Mcmullin, Tami S ^h   Mcqueen, Charlene A ^h   Rowlands, Craig J ^c  

^a Ted Simon LLC   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^f ILSI HEALTH AND ENVIRONMENTAL SCIENCES INSTITUTE   (United States)

^g Consultant ^*  (United States)

^h DOW CHEMICAL COMPANY   (United States)

Author keywords

Associative event; Key event; Mode of action; Modulating factor; Q KEDRF; Risk assessment

Indexed keywords

CHLORPYRIFOS; ESTROGEN; HOST FACTOR; PESTICIDE; CARCINOGEN;

ADVERSE OUTCOME; CHOLINESTERASE INHIBITION; COMPUTER MODEL; CONCEPTUAL FRAMEWORK; DOSE RESPONSE; ENZYME POLYMORPHISM; HISTORY OF MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KEY EVENTS DOSE RESPONSE FRAMEWORK; NEPHROTOXICITY; NONHUMAN; QUANTITATIVE ANALYSIS; QUANTITATIVE STUDY; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; RODENT; THEORETICAL MODEL; TOXICOLOGY; UROTHELIUM; UTEROTROPHY; UTERUS DISEASE; ANIMAL; CHEMISTRY; GOVERNMENT; METABOLISM; PROCEDURES; SPECIES DIFFERENCE; UNITED STATES;

ANIMALS; CARCINOGENS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; SPECIES SPECIFICITY; TOXICOLOGY; UNITED STATES; UNITED STATES ENVIRONMENTAL PROTECTION AGENCY;

EID: 84904960982     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2014.931925     Document Type: Review

References (198)

1. Adami HO, Berry SC, Breckenridge CB, Smith LL, Swenberg JA, Trichopoulos D, et al. (2011). Toxicology and epidemiology: Improving the science with a framework for combining toxicological and epidemiological evidence to establish causal inference. Toxicol Sci, 122, 223-34.
2. Adeleye Y, Andersen M, Clewell R, Davies M, Dent M, Edwards S, et al. (2014). Implementing toxicity testing in the 21st century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment. Toxicology, pii: S0300-483X(14)00032-8. doi: 10.1016/j.tox.2014.02.007. [Epub ahead of print].
3. Adkins S, Gan KN, Mody M, La Du BN. (1993). Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet, 52, 598-608.
4. Albers JW, Berent S, Garabrant DH, Giordani B, Schweitzer SJ, Garrison RP, Richardson RJ. (2004). The effects of occupational exposure to chlorpyrifos on the neurologic examination of central nervous system function: A prospective cohort study. J Occup Environ Med, 46, 367-78.
5. Albers JW, Garabrant DH, Berent S, Richardson RJ. (2010). Paraoxonase status and plasma butyrylcholinesterase activity in chlorpyrifos manufacturing workers. J Expo Sci Environ Epidemiol, 20, 79-89.
6. Albers JW, Garabrant DH, Mattsson JL, Burns CJ, Cohen SS, Sima C, et al. (2007). Dose-effect analyses of occupational chlorpyrifos exposure and peripheral nerve electrophysiology. Toxicol Sci, 97, 196-204.
7. Albers JW, Garabrant DH, Schweitzer S, Garrison RP, Richardson RJ, Berent S. (2004). Absence of sensory neuropathy among workers with occupational exposure to chlorpyrifos. Muscle Nerve, 29, 677-86.
8. Albers JW, Garabrant DH, Schweitzer SJ, Garrison RP, Richardson RJ, Berent S. (2004). The effects of occupational exposure to chlorpyrifos on the peripheral nervous system: A prospective cohort study. Occup Environ Med, 61, 201-11.
9. Alexander BH, Burns CJ, Bartels MJ, Acquavella JF, Mandel JS, Gustin C, Baker BA. (2006). Chlorpyrifos exposure in farm families: Results from the farm family exposure study. J Expo Sci Environ Epidemiol, 16, 447-56.
10. Allegaert K, Vanhaesebrouck S, Verbesselt R, van den Anker JN. (2009). In vivo glucuronidation activity of drugs in neonates: Extensive interindividual variability despite their young age. Ther Drug Monit, 31, 411-15.
11. Andersen ME, Meek E, Boorman GA, Brusick DJ, Cohen SM, Dragan YP, et al. (2000). Lessons learned in applying the US EPA proposed cancer guidelines to specific compounds. Toxicol Sci, 53, 159-72.
12. Andersen ME, Preston RJ, Maier A, Willis AM, Patterson J. (2014). Dose-response approaches for nuclear receptor-mediated modes of action for liver carcinogenicity: Results of a workshop. Crit Rev Toxicol, 44, 50-63.
13. Ankley GT, Bennett RS, Erickson RJ, Hoff DJ, Hornung MW, Johnson RD, et al. (2010). Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem, 29, 730-41.
14. Ashby J, Tinwell H, Soames A, Foster J. (1999). Induction of hyperplasia and increased DNA content in the uterus of immature rats exposed to coumestrol. Environ Health Perspect, 107, 819-22.
15. Aviram M, Dornfeld L, Rosenblat M, Volkova N, Kaplan M, Coleman R, et al. (2000). Pomegranate juice consumption reduces oxidative stress, atherogenic modifications to LDL, and platelet aggregation: Studies in humans and in atherosclerotic apolipoprotein E-deficient mice. Am J Clin Nutr, 71, 1062-76.
16. Beyer LA, Beck BD, Lewandowski TA. (2011). Historical perspective on the use of animal bioassays to predict carcinogenicity: Evolution in design and recognition of utility. Crit Rev Toxicol, 41, 321-38.
17. Blackford JA Jr, Guo C, Zhu R, Dougherty EJ, Chow CC, Simons Jr. S.S. (2012). Identification of location and kinetically defined mechanism of cofactors and reporter genes in the cascade of steroid-regulated transactivation. J Biol Chem, 287, 40982-95.
18. Boekelheide K, Andersen ME (2010). A mechanistic redefinition of adverse effects-A key step in the toxicity testing paradigm shift. ALTEX, 27, 243-52.
19. Boekelheide K, Campion SN. (2010). Toxicity testing in the 21st century: Using the new toxicity testing paradigm to create a taxonomy of adverse effects. Toxicol Sci, 114, 20-4.
20. Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol, 36, 781-92.
21. Boobis AR, Daston GP, Preston RJ, Olin SS. (2009). Application of key events analysis to chemical carcinogens and noncarcinogens. Crit Rev Food Sci Nutr, 49, 690-707.
22. Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, et al. (2008). IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol, 38, 87-96.
23. Borgert CJ, Sargent EV, Casella G, Dietrich DR, McCarty LS, Golden RJ. (2012). The human relevant potency threshold: Reducing uncertainty by human calibration of cumulative risk assessments. Regul Toxicol Pharmacol, 62, 313-28.
24. Bretz F, Pinheiro JC, Branson M. (2005). Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics, 61, 738-48.
25. Briggs K, Cases M, Heard DJ, Pastor M, Pognan F, Sanz F, et al. (2012). Inroads to predict in vivo toxicology-An introduction to the eTOX project. Int J Mol Sci, 13, 3820-46.
26. Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE. (2001). Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet, 68, 1428-36.
27. Brown ES, Jacobs A, Fitzpatrick S. (2012). Reproductive and developmental toxicity testing: From in vivo to in vitro. ALTEX, 29, 333-9.
28. Buchanan RL, Havelaar AH, Smith MA, Whiting RC, Julien E. (2009). The key events dose-response framework: Its potential for application to foodborne pathogenic microorganisms. Crit Rev Food Sci Nutr, 49, 718-28.
29. Budinsky RA, LeCluyse EL, Ferguson SS, Rowlands JC, Simon T. (2010). Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin, 2, 3, 7, 8-Tetrachlorodibenzofuran, and 2, 3, 4, 7, 8-pentachlorodibenzofuran. Toxicol Sci, 118, 224-35.
30. Budinsky RA, Schrenk D, Simon T, van den Berg M, Reichard JF, Silkworth JB, et al. (2014). Mode of action and dose-response framework analysis for receptor-mediated toxicity: The aryl hydrocarbon receptor as a case study. Crit Rev Toxicol, 44, 83-119.
31. Calafat AM, Weuve J, Ye X, Hu H, Ringer S, Huttner K, Hauser R. (2009). Exposure to bisphenol A and other phenols in neonatal intensive care unit premature infants. Environ Health Perspect, 117, 639-44.
32. Chapman K, Holmes M, Seckl J. (2013). 11b-hydroxysteroid dehydrogenases: Intracellular gate-keepers of tissue glucocorticoid action. Physiol Rev, 93, 1139-206.
33. Charlier TD. (2009). Importance of steroid receptor coactivators in the modulation of steroid action on brain and behavior. Psychoneuroendocrino, 34, S20-9.
34. Chow CC, Ong KM, Dougherty EJ, Simons Jr. S.S. (2011). Inferring mechanisms from dose-response curves. Methods Enzymol, 487, 465-83.
35. Clark JH, Markaverich BM. (1984). The agonistic and antagonistic actions of estriol. J Steroid Biochem, 20, 1005-13.
36. Cohen SM. (1995). Role of urinary physiology and chemistry in bladder carcinogenesis. Food Chem Toxicol, 33, 715-30.
37. Cohen SM, Arnold LL. (2011). Chemical carcinogenesis. Toxicol Sci, 120, S76-92.
38. Cohen SM, Arnold LL, Lewis AS, Beck BD. (2006). Methylated arsenicals: The implications of metabolism and carcinogenicity studies in rodents to human risk assessment. Crit Rev Toxicol, 36, 99-133.
39. Cohen SM, Ellwein LB. (1990). Cell proliferation in carcinogenesis. Science, 249, 1007-11.
40. Cohen SM, Klaunig J, Meek ME, Hill RN, Pastoor T, Lehman-Mckeeman L, et al. (2004). Evaluating the human relevance of chemically induced animal tumors. Toxicol Sci, 78, 181-6.
41. Cohen SM, Meek ME, Klaunig JE, Patton DE, Fenner-Crisp PA. (2003). The human relevance of information on carcinogenic modes of action: Overview. Crit Rev Toxicol, 33, 581-9.
42. Conolly RB, Gaylor DW, Lutz WK. (2005). Population variability in biological adaptive responses to DNA damage and the shapes of carcinogen dose-response curves. Toxicol Appl Pharmacol, 207, 570-5.
43. Corton JC, Cunningham ML, Hummer BT, Lau C, Meek B, Peters JM, et al. (2014). Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-Activated receptor alpha (PPARa) as a case study. Crit Rev Toxicol, 44, 1-49.
44. Costa LG, Giordano G, Furlong CE. (2011). Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: The hunt goes on. Biochem Pharmacol, 81, 337-44.
45. Court MH. (2010). Interindividual variability in hepatic drug glucuronidation: Studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev, 42, 209-24.
46. Curtis SW, Washburn T, Sewall C, DiAugustine R, Lindzey J, Couse JF, Korach KS. (1996). Physiological coupling of growth factor and steroid receptor signaling pathways: Estrogen receptor knockout mice lack estrogen-like response to epidermal growth factor. Proc Natl Acad Sci USA, 93, 12626-30.
47. Das SK, Taylor JA, Korach KS, Paria BC, Dey SK, Lubahn DB. (1997). Estrogenic responses in estrogen receptor-Alpha deficient mice reveal a distinct estrogen signaling pathway. Proc Natl Acad Sci USA, 94, 12786-91.
48. De Wildt SN, Kearns GL, Leeder JS, van den Anker JN. (1999). Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet, 36, 439-52.
49. Deakin SP, James RW. (2004). Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin Sci (Lond), 107, 435-47.
50. Dellarco V, Fenner-Crisp PA. (2012). Mode of action: Moving toward a more relevant and efficient assessment paradigm. J. Nutr, 142, 2192S-8S.
51. Dietrich DR (2010)Courage for simplification and imperfection in the 21st century assessment of Endocrine disruption
52. Dougherty EJ, Guo C, Simons SS Jr, Chow, CC. (2012). Deducing the temporal order of cofactor function in ligand-regulated gene transcription: Theory and experimental verification. PLoS One, 7, e30225.
53. EC (European Commission Joint Research Centre). (2003). Technical Guidance Document on Risk Assessment, Part I.I.
54. EC (European Commission) 2008. Regulation (European Commission) No, 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures amending and repealing Directives 67/548/EEC and 1999/45/EEC, and amending Regulation (EC) No. 1907-2006.
55. Edginton AN, Ritter L. (2009). Predicting plasma concentrations of bisphenol A in children younger than 2 years of age after typical feeding schedules, using a physiologically base toxicokinetic model. Environ Health Perspect, 117, 645-52.
56. EFSA (European Food Safety Authority). (2005). Opinion of a Scientific Committee on a request from EFSA related to A Harmonised Approach for Risk Assessment of Substances Which Are Both Genotoxic and Carcinogenic.
57. Elcombe CR, Peffer RC, Wolf DC, Bailey J, Bars R, Bell D, et al. (2014). Mode of action and human relevance analysis for nuclear receptor mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator. Crit Rev Toxicol, 44, 64-82.
58. Evans MV, Dowd SM, Kenyon EM, Hughes MF, El-Masri HA. (2008). A physiologically based pharmacokinetic model for intravenous and ingested dimethylarsinic acid in mice. Toxicol Sci, 104, 250-60.
59. Farley DB, Ford SP, Rosazza, JP. (1992). Increase in uterine peroxidase activity in the rat uterus during oestrogen hyperaemia. J Reprod Fertil, 95, 551-8.
60. Faustman EM, Ponce RA, Seeley MR, Whittaker SG. (1997). Experimental approaches to evaluate mechanisms of developmental toxicity. Handbook of developmental toxicology. New York: CRC Press, Inc;
61. Fisher JW, Twaddle NC, Vanlandingham M, Doerge DR. (2011). Pharmacokinetic modeling: Prediction and evaluation of route dependent dosimetry of bisphenol A in monkeys with extrapolation to humans. Toxicol Appl Pharmacol, 257, 122-36.
62. Furr BJ, Jordan VC. (1984). The pharmacology and clinical uses of tamoxifen. Pharmacol Ther, 25, 127-205.
63. Gamble MV, Hall MN. (2012). Relationship of creatinine and nutrition with arsenic metabolism. Environ Health Perspect, 120, A145-6.
64. Garabrant DH, Aylward LL, Berent S, Chen Q, Timchalk C, Burns CJ, et al. (2009). Cholinesterase inhibition in chlorpyrifos workers: Characterization of biomarkers of exposure and response in relation to urinary TCPy. J Expo Sci Environ Epidemiol, 19, 634-42.
65. Geens T, Aerts D, Berthot C, Bourguignon JP, Goeyens L, Lecomte P, et al. (2012). A review of dietary and non-dietary exposure to bisphenol-A. Food Chem Toxicol, 50, 3725-40.
66. Giangrande PH, Kimbrel EA, Edwards DP, McDonnell DP. (2000). The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. Mol Cell Biol, 20, 3102-15.
67. Girard H, Levesque E, Bellemare J, Journault K, Caillier B, Guillemette C. (2007). Genetic diversity at the UGT1 locus is amplified by a novel 3' alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenet Genomics, 17, 1077-89.
68. Golden RJ, Noller KL, Titus-Ernstoff L, Kaufman RH, Mittendorf R, Stillman R, Reese EA. (1998). Environmental endocrine modulators and human health: An assessment of the biological evidence. Crit Rev Toxicol, 28, 109-227.
69. Gori GB. (2013). Regulatory forum opinion piece: Long-Term animal bioassays: Is the end near? Toxicol Pathol, 41, 805-7.
70. Gorski J, Stormshak F, Harris J, Wertz N. (1977). Hormone regulation of growth: Stimulatory and inhibitory influences of estrogens on DNA synthesis. J Toxicol Environ Health, 3, 271-9.
71. Goutelle S, Maurin M, Rougier F, Barbaut X, Bourguignon L, Ducher M, Maire P. (2008). The Hill equation: A review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol, 22, 633-48.
72. Guillemette C, Levesque E, Harvey M, Bellemare J, Menard V. (2010). UGT genomic diversity: Beyond gene duplication. Drug Metab Rev, 42, 24-44.
73. Guzelian PS, Victoroff MS, Halmes NC, James RC, Guzelian CP. (2005). Evidence-based toxicology: A comprehensive frame-work for causation. Hum Exp Toxicol, 24, 161-201.
74. Hanahan D, Weinberg RA. (2000). The hallmarks of cancer. Cell, 100, 57-70.
75. Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646-74.
76. Hartung T, McBride M. (2011). Food for thought on mapping the human toxome. ALTEX, 28, 83-93.
77. Health Canada. (1999). Voluntary pesticide resistance-management labelling based on target site/mode of action.
78. Health Canada. (2009). Guidelines for Canadian drinking water quality: Guideline technical document-Benzene.
79. Health Canada. (2011). Guidelines for Canadian drinking water quality: Guideline technical document-N-Nitrosodimethylamine (NDMA).
80. Heneweer M, Houtman R, Poortman J, Groot M, Maliepaard C, Peijnenburg A. (2007). Estrogenic effects in the immature rat uterus after dietary exposure to ethinylestradiol and zearalenone using a systems biology approach. Toxicol Sci, 99, 303-14.
81. Hengstler JG, Foth H, Gebel T, Kramer PJ, Lilienblum W, Schweinfurth et al. (2011). Critical evaluation of key evidence on the human health hazards of exposure to bisphenol A. Crit Rev Toxicol, 41, 263-91.
82. Hill AB. (1965). The Environment and disease: Association or Causation? Proc R Soc Med, 58, 295-300.
83. Hill AV. (1910). The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. J. Physiol Proceedings: Iv-vii.
84. Hinderliter PM, Price PS, Bartels MJ, Timchalk C, Poet TS. (2011). Development of a source-To-outcome model for dietary exposures to insecticide residues: An example using chlorpyrifos. Regul Toxicol Pharmacol, 61, 82-92.
85. Huen K, Harley K, Bradman A, Eskenazi B, Holland N. (2010). Longitudinal changes in PON1 enzymatic activities in Mexican-American mothers and children with different genotypes and haplotypes. Toxicol Appl Pharmacol, 244, 181-9.
86. IOM (Institute of Medicine). (2010). Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. The National Academies Press.
87. John S, Sabo PJ, Thurman RE, Sung MH, Biddie SC, Johnson TA, et al. (2011). Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat Genet, 43, 264-8.
88. Judson R, Houck K, Martin M, Knudsen T, Thomas RS, Sipes N, et al. (2014). In Vitro and Modelling Approaches to Risk Assessment from the US Environmental Protection Agency ToxCast Programme. Basic Clin Pharmacol Toxicol, 115, 50-76.
89. Julien E, Boobis AR, Olin SS, Ilsi Research Foundation Threshold Working Group. (2009). The Key Events Dose-Response Framework: A cross-disciplinary mode-of-Action based approach to examining dose-response and thresholds. Crit Rev Food Sci Nutr, 49, 682-9.
90. Kaye AM, Icekson I, Lindner HR. (1971). Stimulation by estrogens of ornithine and S-Adenosylmethionine decarboxylases in the immature rat uterus. Biochim Biophys Acta, 252, 150-9.
91. Kirman CR, Hays SM, Aylward LL, Suh M, Harris MA, Thompson CM, et al. (2012). Physiologically based pharmacokinetic model for rats and mice orally exposed to chromium. Chem Biol Interact, 200, 45-64.
92. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J, et al. (2002). Requirement of estrogen receptor-Alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-Talk. J Biol Chem, 277, 8531-537.
93. Kobayashi S, Stice JP, Kazmin D, Wittmann BM, Kimbrel EA, Edwards DP, et al. (2010). Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. Mol Endocrinol, 24, 2292-302.
94. Koshland DE. (1996). The structural basis of negative cooperativity: Receptors and enzymes. Curr Opin Struct Biol, 6, 757-61.
95. Koshland DE, Hamadani K. (2002). Proteomics and models for enzyme cooperativity. J Biol Chem, 277, 46841-4.
96. Kraus WL, Weis KE, Katzenellenbogen BS. (1995). Inhibitory cross-Talk between steroid hormone receptors: Differential targeting of estrogen receptor in the repression of its transcriptional activity by agonist-And antagonist-occupied progestin receptors. Mol Cell Biol, 15, 1847-57.
97. Krekels EH, Danhof M, Tibboel D, Knibbe CA. (2012). Ontogeny of hepatic glucuronidation; methods and results. Curr Drug Metab, 13, 728-43.
98. Landesmann B, Mennecozzi M, Berggren E, Whelan M. (2013). Adverse outcome pathway-based screening strategies for an animal-free safety assessment of chemicals, Altern Lab Anim, 41, 461-71.
99. Leary FJ, Resseguie LJ, Kurland LT, O'brien PC, Emslander RF, Noller KL. (1984). Males exposed in utero to diethylstilbestrol. JAMA, 252, 2984-9.
100. Lehman-McKeeman LD, Rodriguez PA, Takigiku R, Caudill D, Fey ML. (1989). d-Limonene-induced male rat-specific nephrotoxicity: Evaluation of the association between d-limonene and alpha 2uglobulin. Toxicol Appl Pharmacol, 99, 250-9.
101. Levin E, Actis AM, Lopez S. (1993). Characterization of rat uterine estrogen receptors in vivo. J Steroid Biochem Mol Biol, 44, 277-85.
102. Levine M. (2011). Paused RNA polymerase II as a developmental checkpoint. Cell, 145, 502-11.
103. Levitzki A, Koshland DE. (1969). Negative cooperativity in regulatory enzymes. Proc Natl Acad Sci U. S. A, 62, 1121-8.
104. Liteplo RG, Meek ME. (2003). Inhaled formaldehyde: Exposure estimation, hazard characterization and exposure-response analysis. J Toxicol Environ Health B Crit Rev, 6, 85-114.
105. Lutz WK. (2001). Susceptibility differences in chemical carcinogenesis linearize the dose-response relationship: Threshold doses can be defined only for individuals. Mutat Res, 482, 71-6.
106. Lutz WK, Lutz RW. (2009). Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data. Mutat Res, 678, 118-22.
107. Lyttle CR, Desombre ER. (1977). Uterine peroxidase as a marker for estrogen action. Proc Natl Acad Sci U. S. A, 74, 3162-6.
108. Maier A, Kohrman-Vincent M, Hertzberg R, Allen B, Haber LT, Dourson M. (2012). Critical review of dose-response options for F344 rat mammary tumors for acrylamide-Additional insights based on mode of action. Food Chem Toxicol, 50, 1763-75.
109. Mazur CS, Kenneke JF, Hess-Wilson JK, Lipscomb JC. (2010). Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Drug Metab Dispos, 38, 2232-8.
110. Meek ME. (2008). Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ Mol Mutagen, 49, 110-16.
111. Meek ME, Boobis A, Cote I, Dellarco V, Fotakis G, Munn S, et al. (2014). New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol, 34, 1-18.
112. Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-Mckeeman LD, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit. Rev. Toxicol, 33, 591-653.
113. Meek ME, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. (2014). Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol, 34, 595-606.
114. Mercke Odeberg J, Andradem J, Holmberg K, Hoglund P, Malmqvist U, Odeberg J. (2006). UGT1A polymorphisms in a Swedish cohort and a human diversity panel, and the relation to bilirubin plasma levels in males and females. Eur J Clin Pharmacol, 62, 829-37.
115. Mielke H, Gundert-Remy U. (2009). Bisphenol A levels in blood depend on age and exposure. Toxicol Lett, 190, 32-40.
116. Mileson BE, Chambers JE, Chen WL, Dettbarn W, Ehrich M, Eldefrawi AT, et al. (1998). Common mechanism of toxicity: A case study of organophosphorus pesticides. Toxicol Sci, 41, 8-20.
117. Miyagi SJ, Collier AC. (2011). The development of UDPglucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab Dispos, 39, 912-19.
118. Murrell JA, Portier CJ, Morris RW. (1998). Characterizing dose-response: I: Critical assessment of the benchmark dose concept. Risk Anal, 18, 13-26.
119. Nachman RA, Fox SD, Golden C, Sibinga E, Veenstra TD, Groopman JD, Lees PSJ. (2013). Urinary Free Bisphenol A and Bisphenol A-Glururonide Concentrations in Newborns. J Pediatr, 162, 870-2.
120. Naciff JM, Overmann GJ, Torontali SM, Carr GJ, Tiesman JP, Richardson BD, Daston GP. (2003). Gene expression profile induced by 17 alphaethynyl estradiol in the prepubertal female reproductive system of the rat. Toxicol Sci, 72, 314-30.
121. Navarro SL, Chen Y, Li L, Li SS, Chang JL, Schwarz Y, et al. (2011). UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos, 39, 1650-7.
122. Navarro SL, Peterson S, Chen C, Makar KW, Schwarz Y, King IB, Li SS, Li L, Kestin M, Lampe JW. (2009). Cruciferous vegetable feeding alters UGT1A1 activity: Diet-And genotype-dependent changes in serum bilirubin in a controlled feeding trial. Cancer Prev Res (Phila. Pa), 2, 345-52.
123. Notides AC, Lerner N, Hamilton DE. (1981). Positive cooperativity of the estrogen receptor. Proc Natl Acad Sci U. S. A, 78, 4926-30.
124. NRC (National Research Council). (1983). Risk Assessment in the Federal Government: Managing the Process.
125. NRC (National Research Council). (2007). Toxicity Testing in the Twenty-First Century.
126. NRC (National Research Council) 2009. Science and Decisions: Advancing Risk Assessment. Washington, DC: The National Academies Press.
127. NRC (National Research Council). (2011). Review of the Environmental Protection Agency's Draft IRIS Assessment of Formaldehyde.
128. NTP (National Toxicology Program). (2006). NTP technical report on the toxicology and carcinogenesis studies of 2, 3, 7, 8-Tetrachlorodibenzop-dioxin (TCDD) (CAS No 1746-01-6) in female Harlan Sprague-Dawley rats (Gavage Studies). Nat. Toxicol. Program. Tech. Rep. Ser TR,-521.
129. OECD (Organisation for Economic Co-Operation and Development). (2003). Detailed Background Review of the Uterotrophic Bioassay. ENV/JM/MONO 2003.
130. OECD (Organisation for Economic Co-Operation and Development). (2013). Guidance Document on Developing and Assessing Adverse Outcome Pathways.
131. Ong KM, Blackford JA, Kagan BL, Simons Jr. S.S., Chow CC. (2010). A theoretical framework for gene induction and experimental comparisons. Proc Natl Acad Sci U. S. A, 107, 7107-12.
132. Parisi F, Sonderegger B, Wirapati P, Delorenzi M, Naef F. (2009). Relationship between estrogen receptor alpha location and gene induction reveals the importance of downstream sites and cofactors. BMC Genomics, 10, 381.
133. Patlewicz G, Simon T, Goyak K, Phillips RD, Rowlands JC, Seidel S, Becker RA. (2013). Use and validation of HT/HC assays to support 21st century toxicity evaluations. Regul Toxicol Pharmacol, 65, 259-68
134. Phillips CV, Goodman KJ. (2004). The missed lessons of Sir Austin Bradford Hill. Epidemiol Perspect Innov, 1, 1-5.
135. Phillips CV, Goodman KJ. (2006). Causal criteria and counterfactuals; nothing more (or less) than scientific common sense. Emerg Themes Epidemiol, 3, 1-7.
136. Piccirillo VJ, Bird MG, Lewis RJ, Bover WJ. (2012). Preliminary evaluation of the human relevance of respiratory tumors observed in rodents exposed to naphthalene. Regul Toxicol Pharmacol, 62, 433-40.
137. Popper K. (1959). In The Logic of Scientific Discovery. New York, NY: Republished by Ruteledge
138. Price PS, Schnelle KD, Cleveland CB, Bartels MJ, Hinderliter PM, Timchalk C, Poet TS. (2011). Application of a source-To-outcome model for the assessment of health impacts from dietary exposures to insecticide residues. Regul Toxicol Pharmacol, 61, 23-31.
139. Rao VS, Chaves MC, Ribeiro RA. (1995). Nitric oxide synthase inhibition and the uterotrophic response to oestrogen in immature rats. J Reprod Fertil, 105, 303-6.
140. Reiss R, Neal B, Lamb JC, Juberg DR. (2012). Acetylcholinesterase inhibition dose-response modeling for chlorpyrifos and chlorpyrifosoxon. Regul Toxicol Pharmacol, 63, 124-31.
141. Rhomberg LR, Bailey LA, Goodman JE. (2010). Hypothesis-based weight of evidence: A tool for evaluating and communicating uncertainties and inconsistencies in the large body of evidence in proposing a carcinogenic mode of action-naphthalene as an example. Crit Rev Toxicol, 40, 671-96.
142. Richter RJ, Jarvik GP, Furlong CE. (2009). Paraoxonase 1 (PON1) status and substrate hydrolysis. Toxicol Appl Pharmacol, 235, 1-9.
143. Rock W, Rosenblat M, Miller-Lotan R, Levy AP, Elias M, Aviram M. (2008). Consumption of wonderful variety pomegranate juice and extract by diabetic patients increases paraoxonase 1 association with high-density lipoprotein and stimulates its catalytic activities. J Agric Food Chem, 56, 8704-13.
144. Rodgers IS, Baetcke KP. (1993). Interpretation of male rat renal tubule tumors. Environ Health Perspect, 101, 45-52.
145. Rosenfeld CR, Cox BE, Roy T, Magness RR. (1996). Nitric oxide contributes to estrogen-induced vasodilation of the ovine uterine circulation. J Clin Invest, 98, 2158-66.
146. Ross AC, Russell RM, Miller SA, Munro IC, Rodricks JV, Yetley EA, Julien E. (2009). Application of a key events dose-response analysis to nutrients: A case study with vitamin A (retinol). Crit Rev Food Sci Nutr, 49, 708-17.
147. Rowlands JC, Sander M, Bus JS, Futuretox Organizing Committee. (2014). FutureTox: Building the road for 21st century toxicology and risk assessment practices. Toxicol Sci, 137, 269-77.
148. Sand S, Von Rosen D, Victorin K, Filipsson AF. (2006). Identification of a critical dose level for risk assessment: Developments in benchmark dose analysis of continuous endpoints. Toxicol Sci, 90, 241-51.
149. Saracino MR, Bigler J, Schwarz Y, Chang JL, Li S, Li L, et al. (2009). Citrus fruit intake is associated with lower serum bilirubin concentration among women with the UGT1A1 28 polymorphism. J Nutr, 139, 555-60.
150. Sawilowsky S. (2002). Fermat, Schubert, Einstein and Behrens-Fisher: The Probable Difference Between Two Means When V12 ? V22. J Modern Appl Stat Meth, 1, 461-72.
151. Seed J, Carney EW, Corley RA, Crofton KM, Desesso JM, Foster PM, et al. (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Crit Rev Toxicol, 35, 664-72.
152. Sen B, Wang A, Hester SD, Robertson JL, Wolf DC. (2005). Gene expression profiling of responses to dimethylarsinic in female F344 rat urothelium. Toxicology, 215, 214-26.
153. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U.S.A, 110, 3507-12.
154. Sierksma A, Van Der Gaag MS, Van Tol A, James RW, Hendriks HF. (2002). Kinetics of HDL cholesterol and paraoxonase activity in moderate alcohol consumers. Alcohol Clin Exp Res, 26, 1430-5.
155. Silkworth JB, Koganti A, Illouz K, Possolo A, Zhao M, Hamilton SB. (2005). Comparison of TCDD and PCB CYP1A induction sensitivities in fresh hepatocytes from human donors, sprague-dawley rats, and rhesus monkeys and HepG2 cells. Toxicol Sci, 87, 508-19.
156. Simon T, Aylward LL, Kirman CR, Rowlands JC, Budinsky RA. (2009). Estimates of cancer potency of 2, 3, 7, 8-Tetrachlorodibenzo(p)dioxin using linear and nonlinear dose-response modeling and toxicokinetics. Toxicol Sci, 112, 490-506.
157. Simons Jr. S.S. (2008). What goes on behind closed doors: Physiological versus pharmacological steroid hormone actions. Bioessays, 30, 744-56.
158. Simons Jr. S.S. (2010). Glucocorticoid receptor cofactors as therapeutic targets. Curr Opin Pharmacol, 10, 613-19.
159. Simons SS Jr, Chow CC. (2012). The road less traveled: New views of steroid receptor action from the path of dose-response curves. Mol Cell Endocrinol, 348, 373-82.
160. Slob W, Setzer RW. (2014). Shape and steepness of toxicological doseresponse relationships of continuous endpoints. Crit Rev Toxicol, 44, 270-97.
161. Smith JN, Timchalk C, Bartels MJ, Poet TS. (2011). In vitro agedependent enzymatic metabolism of chlorpyrifos and chlorpyrifosoxon in human hepatic microsomes and chlorpyrifos-oxon in plasma. Drug. Metab. Dispos, 39, 1353-62.
162. Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol, 34, 146-52.
163. Stice SL, Ford SP, Rosazza JP, Van Orden DE. (1987). Interaction of 4-hydroxylated estradiol and potential-sensitive Ca2 ? channels in altering uterine blood flow during the estrous cycle and early pregnancy in gilts. Biol Reprod, 36, 369-75.
164. Stice SL, Ford SP, Rosazza JP, Van Orden DE. (1987). Role of 4-hydroxylated estradiol in reducing Ca2 ? uptake of uterine arterial smooth muscle cells through potential-sensitive channels. Biol Reprod, 36, 361-8.
165. Strassburg CP, Oldhafer K, Manns MP, Tukey RH. (1997). Differential expression of the UGT1A locus in human liver, biliary, and gastric tissue: Identification of UGT1A7 and UGT1A10 transcripts in extrahepatic tissue. Mol Pharmacol, 52, 212-20.
166. Sun Y, Tao YG, Kagan BL, He Y, Simons Jr, SS. (2008). Modulation of transcription parameters in glucocorticoid receptor-mediated repression. Mol Cell Endocrinol, 295, 59-69.
167. Susser M. (1986). The logic of Sir Karl Popper and the practice of
168. Taylor SL, Gendel SM, Houben GF, Julien E. (2009). The Key Events Dose-Response Framework: A foundation for examining variability in elicitation thresholds for food allergens. Crit Rev Food Sci Nutr, 49, 729-39.
169. Teeguarden JG, Waechter JM, Clewell HJ, Covington TR, Barton HA. (2005). Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Toxicol Sci, 85, 823-38.
170. Thomas DJ. (2007). Molecular processes in cellular arsenic metabolism. Toxicol Appl Pharmacol, 222, 365-73.
171. Thomas RS, Black M, Li L, Healy E, Chu TM, Bao W, et al. (2012). A Comprehensive Statistical Analysis of Predicting In Vivo Hazard Using High-Throughput In Vitro Screening. Toxicol Sci, 128, 398-417.
172. Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: Moving from 21st century vision to a data-driven framework. Toxicol Sci, 136, 4-18.
173. Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays SM, et al. (2014). A chronic oral reference dose for hexavalent chromiuminduced intestinal cancer. J Appl Toxicol, 34, 525-36.
174. Timchalk C, Kousba A, Poet TS. (2002). Monte Carlo analysis of the human chlorpyrifos-oxonase (PON1) polymorphism using a physiologically based pharmacokinetic and pharmacodynamic (PBPK/ PD) model. Toxicol Lett, 135, 51-9.
175. Timchalk C, Nolan RJ, Mendrala AL, Dittenber DA, Brzak KA, Mattsson JL. (2002). A Physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol Sci, 66, 34-53.
176. Tukey JW, Ciminera JL, Heyse JF. (1985). Testing the Statistical Certainty of a Response to Increasing Doses of a Drug. Biometrics, 41, 295-301.
177. USEPA (United States Environmental Protection Agency). (2005). Guidelines for Carcinogen Risk Assessment.
178. USEPA (United States Environmental Protection Agency). (2005). Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens.
179. USEPA (United States Environmental Protection Agency). (2005). Science Issue Paper: Mode of Carcinogenic Action for Cacodylic Acid V (Dimethylarsinic Acid, DMA) and Recommendations for Dose Response Extrapolation.
180. USEPA (United States Environmental Protection Agency). (2006). Revised Reregistration Eligibility Decision for MSMA, DSMA, CAMA, and Cacodylic Acid.
181. USEPA (United States Environmental Protection Agency). (2007). Framework for Determining a Mutagenic Mode of Action for Carcinogenicity: Using EPA's 2005 Cancer Guidelines and Supplemental Guidance for Assessing Susceptibility to Early-Life Exposure to Carcinogens.
182. USEPA (United States Environmental Protection Agency). (2011). DRAFT Guidance for Applying Quantitative Data to Develop Data-Derived Extrapolation Factors for Interspecies and Intraspecies Extrapolation.
183. Van Gemert M, Dourson M, Moretto A, Watson M. (2001). Use of human data for the derivation of a reference dose for chlorpyrifos. Regul. Toxicol. Pharmacol, 33, 110-16.
184. Vink R, Mikkers J, Bouwman T, Marquart H, Kroese D. (2010). Use of read-Across and tiered exposure assessment in risk assessment under REACH-A case study on a phase-in substance. Regul Toxicol Pharmacol, 58, 64-71.
185. Vinken M. (2013). The adverse outcome pathway concept: A pragmatic tool in toxicology. Toxicology, 312, 158-65.
186. Waddell WJ. (2005). Comparisons of thresholds for carcinogenicity on linear and logarithmic dosage scales. Hum Exp Toxicol, 24, 325-32.
187. Waddell WJ. (2008). Thermodynamic basis for expressing dose logarithmically. Toxicol Appl Pharmacol, 2, 156-7.
188. Wagner JG. (1968). Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man. J Theor Biol, 20, 173-201.
189. Wen DX, Xu YF, Mais DE, Goldman ME, Mcdonnell DP. (1994). The A and B isoforms of the human progesterone receptor operate through distinct signaling pathways within target cells. Mol. Cell. Biol, 14, 8356-64.
190. Willhite CC, Ball GL, Mclellan CJ. (2008). Derivation of a bisphenol A oral reference dose (RfD) and drinking-water equivalent concentration. J Toxicol Environ Health B Crit Rev, 11, 69-146.
191. Winuthayanon W, Hewitt SC, Orvis GD, Behringer RR, Korach KS. (2010). Uterine epithelial estrogen receptor a is dispensable for proliferation but essential for complete biological and biochemical responses. Proc Natl Acad Sci USA, 107, 19272-7.
192. World Health Organization-International Programme on Chemical Safety (WHO-IPCS). (2005). Chemical-Specific Adjustment Factors for Interspecies Differences and Human Variability: Guidance Document for Use of Data in Dose/Concentration Response Assessment.
193. Yamasaki K, Noda S, Imatanaka N, Yakabe Y. (2004). Comparative study of the uterotrophic potency of 14 chemicals in a uterotrophic assay and their receptor-binding affinity. Toxicol Lett, 146, 111-20.
194. Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Imatanaka N, Takatsuki M. (2002). Comparison of reporter gene assay and immature rat uterotrophic assay of twenty-Three chemicals. Toxicology, 170, 21-30.
195. Yamasaki K, Takeyoshi M, Yakabe Y, Sawaki M, Takatsuki M. (2003). Comparison of the reporter gene assay for ER-Alpha antagonists with the immature rat uterotrophic assay of 10 chemicals. Toxicol Lett, 142, 119-31.
196. Ye X, Zhou X, Wong LY, Calafat AM. (2012). Concentrations of bisphenol a and seven other phenols in pooled sera from 3-11 year old children: 2001-2002 national health and nutrition examination survey. Environ Sci Technol, 46, 12664-71.
197. Zhang Z, Sun Y, Cho YW, Chow CC, Simons SS. (2012). PA1: A New Competitive Decelerator Acting at More Than One Step To Impede Glucocorticoid Receptor-Mediated Transactivation. J. Biol. Chem, 288, 42-58.
198. Zhang Z, Teng CT. (2001). Estrogen receptor alpha and estrogen receptorrelated receptor alpha1 compete for binding and coactivator. Mol Cell Endocrinol, 172223-33.